In contrast, when EGFR mutations were observed in low-grade gliomas, they were associated poor outcomes, but EGFR mutations were non-prognostic in high-grade glioblastomas (Figure 1—figure supplement 7D). This evidence concerns the gene EGFR and central nervous system cancer.